Donatello Crocetta, Chief Medical Officer at UCB, said: “These results for bimekizumab show meaningful improvements in inflammatory lesions and skin pain to three years, and offer a valuable ...
Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...
Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast ...
Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of DT-7012, a ...
Incyte has announced promising new data from its phase 3b TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD), revealing significant improvements in clinical ...
ProImmune has announced the launch of its ProVE SL Self-Loading MHC Class I Monomers, a new reagent platform designed to enhance antigen-specific CD8+ T cell detection. The Oxford-based life science ...
Faster scans and same-day results improve patient experience across community sites United Lincolnshire Teaching Hospitals NHS Trust has upgraded its three Community Diagnostics Centres (CDCs) in ...
In this edition we dare to dream – fever dream, no less – about the future of the NHS. We go beyond the current chaos and speculate about the possibilities built on the founding principles, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback